A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides
| Autor: | Neelie Zacharias, Vladimir N. Podust, Kimberly K. Kajihara, Douglas Leipold, Geoffrey Del Rosario, Desiree Thayer, Emily Dong, Maciej Paluch, David Fischer, Kai Zheng, Corinna Lei, Jintang He, Carl Ng, Dian Su, Luna Liu, Shabkhaiz Masih, William Sawyer, Jeff Tinianow, Jan Marik, Victor Yip, Guangmin Li, Josefa Chuh, J. Hiroshi Morisaki, Summer Park, Bing Zheng, Hilda Hernandez-Barry, Kelly M. Loyet, Min Xu, Katherine R. Kozak, Gail Lewis Phillips, Ben-Quan Shen, Cong Wu, Keyang Xu, Shang-Fan Yu, Amrita Kamath, Rebecca K. Rowntree, Dorothea Reilly, Thomas Pillow, Andrew Polson, Volker Schellenberger, Wouter L. W. Hazenbos, Jack Sadowsky |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Chemical Science. 13:3147-3160 |
| ISSN: | 2041-6539 2041-6520 |
| Popis: | The antibody-drug conjugate (ADC) is a well-validated modality for the cell-specific delivery of small molecules with impact expanding rapidly beyond their originally-intended purpose of treating cancer. However, antibody-mediated delivery (AMD) remains inefficient, limiting its applicability to targeting highly potent payloads to cells with high antigen expression. Maximizing the number of payloads delivered per antibody is one key way in which delivery efficiency can be improved, although this has been challenging to carry out; with few exceptions, increasing the drug-to-antibody ratio (DAR) above ∼4 typically destroys the biophysical properties and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|